Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.83 |
| ▸ | CA1 | P00915 | 4/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616998 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL28237938 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL28156543 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL3628614 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL1668977 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL5090059 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL3859929 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL6119566 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL10706703 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL22235759 | 0.98 | CA2 (0.80) | CA2CA1MAPK1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | claimed |
| CN-115151534-B | Inhibitors of interleukin-1 receptor associated kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof and methods of use thereof | 南京药石科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-116648451-A | Antagonist compounds | 阿道尔克斯治疗有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | claimed |
| CN-115151534-A | Inhibitors of interleukin-1 receptor-related kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | claimed |
| CN-112423746-A | Novel anti-mycobacterial heterocyclic amides | 克莱斯通公司 | 2021-02-26 | — | — | CN | claimed |
| EP-3753926-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-12-23 | — | — | EP | claimed |
| CN-111699174-A | Spiro compound used as indoleamine-2, 3-dioxygenase inhibitor | 中国科学院上海有机化学研究所 | 2020-09-22 | — | — | CN | claimed |
| CN-101868464-B | Thienopyrimidiene derivatives as PI3k inhibitors | HOFFMANN LA ROCHE | 2013-11-13 | — | — | CN | claimed |
| EP-2486034-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011044197-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | claimed |
| CN-101868464-A | Thienopyrimidiene derivatives as PI3k inhibitors | HOFFMANN LA ROCHE | 2010-10-20 | — | — | CN | claimed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | claimed |
| CN-1399639-A | Novel oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-02-26 | — | — | CN | claimed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | claimed |
| JP-62215537-A | — | — | None | — | — | JP | disclosed |
| JP-S62215537-A | ENDERMIC ABSORPTION PROMOTE AND EXTERNAL PREPARATION CONTAINING SAME | KAO CORP | 1987-09-22 | — | — | JP | disclosed |